fosamprenavir has been researched along with tasosartan in 1 studies
| Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (tasosartan) | Trials (tasosartan) | Recent Studies (post-2010) (tasosartan) |
|---|---|---|---|---|---|
| 174 | 55 | 37 | 25 | 6 | 8 |
| Protein | Taxonomy | fosamprenavir (IC50) | tasosartan (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.032 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0032 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0032 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.035 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for fosamprenavir and tasosartan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |